SCA
ITCI

Spearhead Capital Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Spearhead Capital Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,401
Closed -$365K – 178
2022
Q2 		$365K Sell
6,401
-82
-1% -$4.65K 0.05% 101
2022
Q1 		$397K Buy
+6,483
New +$337K 0.05% 101

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Spearhead Capital Advisors's ITCI Position: Q3 2022 in Review

Spearhead Capital Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2022, closing a stake of 6,401 shares — an estimated $365K sold.

Spearhead Capital Advisors first reported a position in ITCI in Q1 2022 and held it in 2 quarters. The position peaked at $397K in Q1 2022. 274 funds tracked by Wall St. Rank hold ITCI as of Q3 2022.

  • Spearhead Capital Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 6,401 Intra-Cellular Therapies Inc. shares in Q3 2022, an estimated $365K.
  • Spearhead Capital Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 2 quarters.
  • Spearhead Capital Advisors's Intra-Cellular Therapies Inc. position peaked at $397K in Q1 2022.
  • 274 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.